Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression

Fig. 5

Exhaustive evaluation of marker combinations in a depressive subgroup. Top: cross-validation performances of all tested parameter combinations: left, models with higher mean of sensitivity and specificity; right, models with lower performance. Bottom: corresponding parameter combinations: coloured rectangle, corresponding parameter is used in the model; white rectangle, corresponding parameter is not used. The different parameters are ranked according to their frequency in the top models. In the top-performing models, “cGMP” is used most frequently followed by “Albumin” and “AgeAtLP”. AD Alzheimer’s disease, cAMP cyclic adenosine-3',5'-monophosphate, cGMP cyclic guanosine-3',5'-monophosphate (Colour figure online)

Back to article page